Auris Medical Holding AG (EARS) Expected to Earn Q3 2016 Earnings of ($0.29) Per Share
Auris Medical Holding AG (NASDAQ:EARS) – Investment analysts at Leerink Swann issued their Q3 2016 EPS estimates for Auris Medical Holding AG in a research note issued on Tuesday. Leerink Swann analyst J. Schwartz forecasts that the firm will post earnings per share of ($0.29) for the quarter. Leerink Swann also issued estimates for Auris Medical Holding AG’s Q4 2016 earnings at ($0.31) EPS, FY2016 earnings at ($1.11) EPS, FY2017 earnings at ($0.85) EPS and FY2018 earnings at ($0.95) EPS.
Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research raised Auris Medical Holding AG from a “sell” rating to a “hold” rating in a research report on Thursday, September 29th. Needham & Company LLC lifted their price target on Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, August 19th. Finally, JMP Securities lowered Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 18th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Auris Medical Holding AG currently has a consensus rating of “Buy” and an average price target of $8.88.
Shares of Auris Medical Holding AG (NASDAQ:EARS) traded down 8.51% on Friday, hitting $1.29. The stock had a trading volume of 217,154 shares. The firm has a 50 day moving average of $1.71 and a 200 day moving average of $3.25. The stock’s market cap is $44.28 million. Auris Medical Holding AG has a 12 month low of $1.29 and a 12 month high of $7.96.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bellevue Group AG bought a new position in Auris Medical Holding AG during the first quarter worth about $7,897,000. TFS Capital LLC raised its position in Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock worth $160,000 after buying an additional 5,762 shares during the last quarter. Finally, Advisor Group Inc. bought a new position in Auris Medical Holding AG during the second quarter worth about $277,000. 30.95% of the stock is currently owned by institutional investors and hedge funds.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.